DoctorsJesse L. Berry, MD

Jesse L. Berry, MD

Title: Associate Professor of Ophthalmology (Clinical Scholar), Associate Director of Ocular Oncology at Children's Hospital Los Angeles (CHLA) and USC Roski Eye Institute

Department: Ophthalmology

Clinical Specialty: Ocular Oncology and Pediatric Ophthalmology

Treatment Expertise: Ocular Oncology/Eye Cancer including Conjunctival Tumors, Ocular Surface Squamous Neoplasia, Conjunctival Melanoma, Primary Acquired Melanosis, Iris Tumors, Iris Melanoma, Intraocular Tumors, Ciliary Body Tumors, Uveal Melanoma, Intraocular Lymphoma, Vitreoretinal Lymphoma, Uveal Lymphoma, Choroidal, Iris and Conjunctival Nevi

Certification: American Board of Ophthalmology

Languages: English, Spanish

Location: Los Angeles and Children’s Hospital Los Angeles

Research Topics:

Retinoblastoma
Choroidal Melanoma
Ocular Oncology
Clinical Outcomes

Biography and Education

Biography:

Jesse L. Berry, MD is a board-certified ophthalmologist with subspecialty training in ocular oncology. She received her undergraduate and medical degree from Harvard University in Massachusetts. Following her ophthalmology residency at the University of Southern California, she was the Assistant Chief of Service at the Los Angeles County Medical Center. She completed a fellowship in Ocular Oncology at Children’s Hospital Los Angeles under the mentorship of Drs. Jonathan Kim and A. Linn Murphree.

She currently serves as the Associate Director of Ocular Oncology at USC and CHLA and actively treats patients with retinoblastoma, uveal melanoma, intraocular and ocular surface tumors. Dr. Berry is active academically within the broader field of ophthalmology and ocular oncology. She is the Executive Secretary for the International Society of Ocular Oncology and was the conference president for the biennial meeting in Los Angeles in 2019. She is an active advocate for mentorship and opportunities for young ophthalmologists. As such, she is a member of the Young Ophthalmologist committee through the American Academy of Ophthalmology and co-leads the committee for young ophthalmic oncologists and pathologists (YOOPs). Dr. Berry is active within the Women in Ophthalmology organization and is the founder of WOO, Women in Ocular Oncology.

As a physician-scientist, Dr. Berry studies outcomes for retinoblastoma, melanoma and other tumors. Her main interest is the development of the aqueous humor as a liquid biopsy for retinoblastoma and other intraocular disease. She was awarded a K08 from the National Cancer Institute of the National Institute of Health in 2018 to further study this.

In 2019 she was promoted to Associate Professor of Ophthalmology, Clinical Scholar, a special distinction provided by USC.

Dr. Jesse Berry has served as a medical expert on the following USCREI posts:

Research Interests:

Evaluation of the aqueous humor for tumor-derived genetic information and its application to prognosis and precision medicine for retinoblastoma patients. Investigating new methods of chemotherapy delivery for the treatment of Retinoblastoma. Evaluating treatment outcomes for Retinoblastoma eyes. This includes evaluation of treatment outcomes after systemic chemotherapy and the elucidation of factors present at diagnosis, which contribute to final visual outcome in eyes treated for retinoblastoma.

Watch Dr. Berry discuss her latest research at the AAO 2017 Conference in New Orleans, Louisiana!

Education:

  • BA, Harvard College, Biochemical Sciences, 2004
  • MD, Harvard Medical School, Medicine, 2008

Internship:

  • Memorial Sloan Kettering Cancer Center, 2008-2009

Residency:

  • LAC+USC, Ophthalmology, 2009-2012

Fellowship:

  • CHLA, USC, Ocular Oncology, 2013-2014

Accomplishments

Professional society memberships:

  • International Society of Ocular Oncology (ISOO)
  • American Academy of Ophthalmology (AAO)
  • Association for Research in Vision & Ophthalmology (ARVO)
  • California Association of Eye Physicians & Surgeons (CAEPS)
  • LA Society of Ophthalmology (LASO)
  • Women in Ophthalmology (WIO)
  • Pan American Association of Ophthalmology
  • WE C Hope/1 RB World
  • American Eye Study Club
  • Children’s Oncology Group
  • American Association of the Ophthalmic Oncologists and Pathologists
  • European Ocular Oncology Group (OOG)
  • American Ophthalmological Society (AOS), Candidate for Membership

Awards:

  • Harvard College Scholarship: Elizabeth Cary Agassiz Scholar, 2000-2004
  • Malcolm Kinsberg Scholarship, 2000-2004
  • Kappa Alpha Theta Foundation Scholarship, 2002
  • David Rockefeller Center of Latin American Studies Grant, 2003
  • Nevil & Louise Ford Scholarship Fund, 2004-2008
  • Harvard Medical International Initiatives in Research Grant, 2005
  • Center for Eye Research and Education McCleary Grant, 2007
  • Department of Ophthalmology, USC, Medical Knowledge Award, 2011
  • Starr Schulman Fellowship, 2012
  • Department of Health Services Innovation Grant, 2012
  • Heed Ophthalmic Foundation Fellow, 2013-2014
  • Society of Heed Fellows, 2013
  • University of Southern California Excellence in Resident Teaching Award, 2013
  • University of Southern California Excellence in Resident Teaching Award, 2014
  • Best Paper, Ocular Oncology, American Academy of Ophthalmology, 2017
  • Women Leadership Development, Association for Research in Vision, 2018
  • ARVO Travel Grant for Research, 2018
  • University of Southern California Excellence in Resident Teaching Award, 2018
  • AAO 2019 Secretariat Award, 2019
  • AAO Achievement Award, 2019
  • Merit Award, The Saban Research Institute, 2019

Publications:

  1. Berry JL, Xu L, Murphree AL, Krishnan S, Stachelek K, Zolfoghari E*, McGovern K, Lee TC, Carlsson A, Kuhn P, Kim JK, Cobrinik D, Hicks J. Potential of Aqueous Humor as a Surrogate Biopsy for Retinoblastoma. JAMA Ophthalmol. 135(11): 1221-1230, 2017. PMID#29049475, PMCID#PMC5710399
  2. Berry JL, Xu L, Kooi I, Murphree AL, Prabakar RK*, Reid M, Stachelek K, Le BA*, Welter L, Reiser BJ, Chevez Barrios P, Jubran R, Lee TC, Kim JK, Kuhn P, Cobrinik D, Hicks J. Genomic cfDNA Analysis of Aqueous Humor in Retinoblastoma Predicts Eye Salvage: The Surrogate Tumor Biopsy for Retinoblastoma. Molecular Cancer Research. 16(11):1701-1712, 2018. PMID#30061186. PMCID# PMC6214755
  3. Berry JL, Xu L, Polski A*, Jubran R, Kuhn P, Kim JW, Hicks J. Aqueous Humor is Superior to Blood as a Liquid Biopsy for Retinoblastoma. Ophthalmol. 2019. doi.org/10.1016/j.ophtha.2019.10.026
  4. Gudiseva H+, Berry JL+, Polski A*, Tummina S, O’Brien JM. Next Generation Technologies and Strategies for the Management of Retinoblastoma. Genes. 2019, 10 (12), 1032. doi.org/10.3390/genes10121032
  5. Berry JL, Kim JW, Jenelle R, Astrahan MA. Use of the Toric Surgical Marker to aid in Intraoperative plaque placement for the USC Eye Physics Plaques to Treat Uveal Melanoma: a New Surgical Technique. Ophthalmic Surg Lasers Imaging Retina. 46(8):866-870, 2015. PMID#26431303
  6. Le BA, Kim JW, Deng H, Rayess N, Jennelle RL, Zhou SY, Astrahan MA, Berry JL. Outcomes of Choroidal Melanomas Treated with Eye Physics Plaques: 25-Year Review. Brachytherapy. 17(6):981-989, 2018.